慢性阻塞性肺疾病（COPD）中的低氧血症及其管理。

The hypoxaemia in chronic obstructive pulmonary disease (COPD) and its management.

作者信息

Voisin C

机构信息

Hopital Albert Calmette, Service de Pneumonologie, Lille, France.

出版信息

Wiad Lek. 1998;51(1-2):11-4.

PMID:9608825

Abstract

Chronic hypoxaemia < or = 55 mmHg, induces various clinical and physiological consequences in patients with stable COPD: dyspnoea, decrease in exercise performances, erythrocytosis impairment of neuropsychological functions, pulmonary hypertension, right ventricular heart failure, all of these troubles impairing quality of life and vital prognosis. To restore a PaO2 > 60 mmHg (or SaO2 > 90%), long term oxygen therapy (LTOT) is the best method in the management of COPD with severe chronic respiratory failure. For patients with PaO2 55-70 mmHg. Almitrine bismesylate a piperazine derivative improving the ventilation/perfusion matching, used in low dosage and in sequential administration, is a useful drug to increase the PaO2 and so, to delay but not to avoid LTOT in responder patients when PaO2 remains < or = 55 mmHg.

摘要

慢性低氧血症（≤55mmHg）会在稳定期慢性阻塞性肺疾病（COPD）患者中引发各种临床和生理后果：呼吸困难、运动能力下降、红细胞增多、神经心理功能受损、肺动脉高压、右心室心力衰竭，所有这些问题都会损害生活质量和重要预后。为了使动脉血氧分压（PaO2）恢复至＞60mmHg（或动脉血氧饱和度（SaO2）＞90%），长期氧疗（LTOT）是治疗伴有严重慢性呼吸衰竭的COPD的最佳方法。对于PaO2为55 - 70mmHg的患者。阿米三嗪萝巴新，一种哌嗪衍生物，可改善通气/血流匹配，小剂量序贯使用时，是一种有助于提高PaO2的药物，因此，当PaO2仍≤55mmHg时，对于有反应的患者可延迟但无法避免LTOT。